

22. (New) The mouse of Claim 21, wherein the allergic disorder is selected from the group consisting of atopic dermatitis, atopic asthma, conjunctival allergy, allergic rhinitis, food allergy, urticaria, contact dermatitis, allergic reactions to drugs, anaphylaxis, autoimmune disease, organ transplant rejection and allo- or xeno-tissue transplant rejection.

23. (New) The mouse of Claim 21, wherein the allergic disorder is atopic dermatitis.

24. (New) The mouse of Claim 21, which has been impregnated with a mite extract.

25. (New) A method of producing the mouse of Claim 21, comprising:
maintaining a NC/Nga mouse in a Specific Pathogen Free environment and
impregnating the animal with the extract of the antigen.

26. (New) The method of Claim 25, wherein the animal is impregnated with the extract of the antigen for at least 5 days.

27. (New) A method of screening for an agent for effectiveness against an allergic disorder, comprising:

applying at least one agent to the mouse of Claim 21,
determining whether the agent reduced the allergy symptom and/or in vitro disorder,
correlating a reduction in the allergy symptom and/or in vitro disorder with
effectiveness against the allergic disorder, and

correlating a lack of reduction in the allergy symptom and/or in vitro disorder with
ineffectiveness against the allergic disorder.

28. (New) The method of Claim 27, wherein the allergic disorder is selected from the group consisting of atopic dermatitis, atopic asthma, conjunctival allergy, allergic rhinitis, food allergy, urticaria, contact dermatitis, allergic reactions to drugs, anaphylaxis, autoimmune disease, organ transplant rejection and allo- or xeno-tissue transplant rejection.--